iSpecimen’s mission is to accelerate life science research and development, or R&D, with a global marketplace platform that connects researchers to subjects, specimens and associated data. Our vision is to create an “Amazon-like” global Marketplace of patients, biospecimens and data for research to improve the quality of human life.
iSpecimen is a technology-driven company founded to address a critical challenge: how to connect life science researchers who need human biofluids, tissues and living cells (“biospecimens”) for their research with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.
The iSpecimen Marketplace brings new capabilities to a highly fragmented and inefficient biospecimen procurement market. Our technology consolidates the biospecimen buying experience in a single online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia and government institutions who need them. We are seeking to transform the world of biospecimen procurement much like the way travel websites changed the consumer buying process for flights, hotels and rental cars.
(Note: iSpecimen priced its IPO on June 16, 2021, at $8 – the low end of its $8-to-$10 range – on 2.25 million shares – an increase of 27,778 shares from the 2.22 million in the prospectus – to raise $18 million.)
|Address||450 Bedford Street Lexington, MA 02420|
|Phone Number||(781) 301-6700|
|View Prospectus:||iSpecimen Inc.|
|Revenues||$8.18 mil (last 12 months)|
|Net Income||$-4.65 mil (last 12 months)|
|Price range||$8.00 - $8.00|
|Est. $ Volume||$18.0 mil|
|Manager / Joint Managers||ThinkEquity|
|Expected To Trade:||6/17/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|